好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Regulatory T cells in the CNS Impact Microglia Instead of Lymphocytes
Autoimmune Neurology
P1 - Poster Session 1 (5:30 PM-6:30 PM)
15-087

To unravel CNS-specific effects of regulatory Foxp3+ T cells (Tregs) in experimental neuroinflammation.


Pathology driving T helper (Th)17 cells can be suppressed in their activity and effector mechanisms. However, it is not known whether regulating mechanisms succeed once pathologic T cells have entered the CNS.


We applied intra-vital two-photon laser scanning microscopy, flow cytometry, histology and RNA-sequencing in Th17 adoptive transfer models.


Strikingly, suppressive effects of Tregs on autoreactive T cells in the CNS are strictly antigen-specific. While transfer of antigen-specific Tregs ameliorated or even prevented experimental autoimmune encephalomyelitis (EAE) symptoms, non-antigen-specific Tregs failed to do so. Using live imaging, functional heterogeneity of Th17 cells and Tregs is characterized by largely distinct motility profiles and interaction parameters, whereby Th17 cells screen and interact with potential targets and Tregs reveal a place-bound behavior. As in other proinflammatory environments, suppressive effects of Tregs are supported by increased motility and reduced overall contacts of Th17 cells while undergoing frequent transient interactions with Tregs. In contrast, Tregs formed preferentially stable and long-lasting contacts with microglia cells. RNA-sequencing of microglia isolated from EAE mice revealed distinct phenotypical changes induced by Treg contacts.


Instead of directly influencing T effector cells as known from the peripheral immune system, antigen-specific Tregs mediate their suppressive effect in the inflamed CNS via modulation of microglia activity.


Authors/Disclosures
Stefan Bittner
PRESENTER
Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Biogen Idec. Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Merck Healthcare. Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Novartis. Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Roche. Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Sanofi. Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Bristol-Meyer-Squibbs. Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Teva.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Frauke Zipp, MD (University Medical Center Mainz) Dr. Zipp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene. Dr. Zipp has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Zipp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Octapharma. Dr. Zipp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Zipp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Zipp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TEVA. The institution of Dr. Zipp has received research support from BMBF. The institution of Dr. Zipp has received research support from DFG. The institution of Dr. Zipp has received research support from PMSA. The institution of Dr. Zipp has received research support from Sanofi Genzyme. The institution of Dr. Zipp has received research support from UCB. The institution of Dr. Zipp has received research support from Eisai. The institution of Dr. Zipp has received research support from SK Life Science. The institution of Dr. Zipp has received research support from Abbott. The institution of Dr. Zipp has received research support from Actelion. The institution of Dr. Zipp has received research support from Bayer. The institution of Dr. Zipp has received research support from Servier. Dr. Zipp has received personal compensation in the range of $500-$4,999 for serving as a Reviewer with Novartis. Dr. Zipp has received personal compensation in the range of $0-$499 for serving as a Reviewer with Universite de Geneve. Dr. Zipp has received personal compensation in the range of $5,000-$9,999 for serving as a Reviewer with Oppenheim Förderpreis für Multiple Sklerose. Dr. Zipp has received personal compensation in the range of $500-$4,999 for serving as a Reviewer with EKFS. Dr. Zipp has a non-compensated relationship as a Associate Editor with Brain that is relevant to AAN interests or activities. Dr. Zipp has a non-compensated relationship as a Advisor with Science Translational Medicine that is relevant to AAN interests or activities.